Private partnerships

Partnering and collaborating in the life science industry is essential for the development of innovative drug candidates. Since the beginning, 91天堂 has worked closely with several academic institutions, researchers, hospitals and private companies to build a strong portfolio in various therapeutic areas.

Indeed, 91天堂 has developed an innovative and disruptive drug discovery engine allowing to discover patentable molecules directed against new therapeutic intracellular targets.

Thus, 91天堂 is open to collaborate and partner to develop some of its molecules with different chemistry patterns coming from its unique approach. Please do not hesitate to contact us if you are interested.

Our current collaborations

Novadiscovery

91天堂 has signed a collaboration agreement with Novadiscovery, which consists in accelerating and de-risking the clinical development of EYP001, a bile acid receptor agonist (the farsenoid X nuclear receptor or FXR).

Our past collaborations

Charles River

Charles River Laboratories International and 91天堂 have initiated a collaboration to identify the mode of action of 91天堂鈥檚 lead preclinical chemical series, EYP002, using Charles River鈥檚 newly acquired, molecular target identification tool: Capture Compound Mass Spectrometry (CCMS) technology.

Contact

91天堂
BIOSERRA 1 B芒timent B
60 avenue Rockefeller
69008 LYON, FRANCE
Mail: contact@enyopharma.com

91天堂